Tirzepatide vs Survodutide
Both Tirzepatide and Survodutide are used for weight-loss and metabolic. Here's how their evidence, dosing, and regulatory status actually compare.
Tirzepatide
Evidence A+Tirzepatide (Mounjaro / Zepbound)
A dual GIP/GLP-1 receptor agonist that achieved up to 22.5% mean weight loss in the SURMOUNT-1 trial — the highest of any FDA-approved weight loss medication.
View full Tirzepatide profile →Survodutide
Evidence ASurvodutide (BI 456906)
A dual GLP-1 / glucagon receptor agonist with strong Phase 2 weight-loss and MASH data. Resolution of MASH in 83% of participants at the highest dose at week 48.
View full Survodutide profile →Side-by-Side
| Attribute | Tirzepatide | Survodutide |
|---|---|---|
| Evidence Grade | A+ | A |
| FDA Status | FDA-approved for weight management and type 2 diabetes | Not FDA-approved — Phase 3 trials for obesity and MASH |
| Typical Dose | 2.5–15 mg weekly (subcutaneous injection) | Trial range: 0.6–6 mg weekly (subcutaneous) |
| Clinics Indexed | 1,850 | 6 |
| Categories | weight-loss, metabolic | weight-loss, metabolic |
Key reported benefits — Tirzepatide
- ✓Superior weight loss
- ✓Dual hormone targeting
- ✓Blood sugar control
- ✓Reduced cardiovascular risk
Key reported benefits — Survodutide
- ✓Weight loss
- ✓MASH resolution
- ✓Glucose control
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.